Roivant Sciences

Yahoo Finance • 8 days ago

Roivant anticipates $950M Moderna payment in July as it outlines 2H 2026 mosliciguat and IMVT-1402 readouts

Earnings Call Insights: Roivant Sciences Ltd. (ROIV) Q4 2025 MANAGEMENT VIEW * CEO Matthew Gline said the quarter included “the preliminary open-label period data from the 1402 study in D2T RA” and a “planned spotlight… on mosliciguat,... Full story

Yahoo Finance • 8 days ago

Roivant (ROIV) Q4 2025 Earnings Transcript

Image source: The Motley Fool. DATE Wednesday, May 20, 2026 at 8 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Matthew GlineUnknown Executive (Mosliciguat program lead) Need a quote from a Motley Fool analyst? Email pr@fool.com... Full story

Yahoo Finance • 8 days ago

Can a New Arthritis Drug Make Immunovant the Next Biotech Star?

Immunovant reports clinically meaningful trial results for its lead drug candidate. That’s good news for Roivant Sciences. Continue Reading... Full story

Yahoo Finance • 8 days ago

These Two Biotech Stocks Rocketed — And One Just Broke Out

Immunovant stock shot to a two-year high Wednesday on "highly compelling" results for its experimental rheumatoid arthritis treatment. Continue Reading... Full story

Yahoo Finance • 8 days ago

2 Biotech Stocks Are Surging Today Thanks to This Arthritis Drug

Immunovant reports clinically meaningful trial results for its lead drug candidate. That’s good news for Roivant Sciences. Continue Reading... Full story

Yahoo Finance • 8 days ago

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update

Roivant Sciences IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA); Immunovant will provi... Full story

Yahoo Finance • 9 days ago

Here are the major earnings before the open Wednesday

Major earnings expected before the bell on Wednesday include: * Target Corporation (TGT [https://seekingalpha.com/symbol/TGT]) * Lowe's Companies (LOW [https://seekingalpha.com/symbol/LOW]) * ZIM Integrated Shipping Services Ltd. (Z... Full story

Yahoo Finance • 10 days ago

Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy?

Key Points Initiated 1,446,375-share position in Beam Therapeutics; estimated trade size $40.13 million (quarterly average price). Quarter-end stake valued at $34.47 million, a net position change reflecting both trading and price movemen... Full story

Yahoo Finance • 10 days ago

Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy?

Key Points ADAR1 Capital Management added 829,963 shares of Crinetics Pharmaceuticals; estimated trade size $37.07 million based on quarterly average pricing. Quarter-end position value increased by $26.98 million, reflecting both trading... Full story

Yahoo Finance • 10 days ago

Myasthenia Gravis Market Set to Surpass USD 16 Billion by 2036, Fueled by Rising Diagnosed Prevalence and Wave of Targeted Biologic Approvals | DelveInsight

DelveInsight Business Research LLP The myasthenia gravis market size reached approximately USD 6 billion in 2025 across the 7MM and is growing at a robust CAGR of 9.1% during the forecast period. This remarkable growth is being underpinne... Full story

Yahoo Finance • 12 days ago

Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares

What happened According to a Securities and Exchange Commission (SEC) filing dated May 15, 2026, Patient Square Capital LP disclosed the purchase of 210,000 shares of Nektar Therapeutics(NASDAQ:NKTR). The estimated value of the trade was... Full story

Yahoo Finance • 24 days ago

Here’s Why Roivant Sciences Ltd (ROIV) Rallied in Q1

Baron Capital, an investment management company, released its Q1 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. Baron Health Care Fund (the Fund) declined 6.97% (Institutional Sha... Full story

Yahoo Finance • last month

Roivant Sciences Ltd. (ROIV): One of the Best Stocks to Buy According to Joe Edelman

We just covered the Billionaire Joe Edelman’s 10 Stock Picks with Huge Upside Potential and Roivant Sciences Ltd. (NASDAQ:ROIV) ranks 8th on this list. Roivant Sciences Ltd. (NASDAQ:ROIV) recently won a major legal battle. In March, Roiva... Full story

Yahoo Finance • 2 months ago

This Biotech ETF Is Still Well Below Its 2021 Peak. Analysts Say That Is Exactly Why to Buy It.

Quick Read The State Street SPDR S&P Biotech ETF (XBI) has gained 58% over the past year and trades at $128, with potential for nearly 50 points of upside to reach its 2021 all-time high of $175. Top holdings include Moderna (2.25%), Roiv... Full story

Yahoo Finance • 2 months ago

Immunovant falls on late-stage trial setback for TED therapy

[Stethoscope with the word Thyroid Disorders.] Fauzi Muda/iStock via Getty Images Immunovant (IMVT [https://seekingalpha.com/symbol/IMVT]) shares lost ~10% in the premarket on Thursday after the company, a subsidiary of Roivant Sciences (... Full story

Yahoo Finance • 2 months ago

Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no FDA-approved therapies exist for LPP, high... Full story

Yahoo Finance • 2 months ago

Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)

Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no FDA-approved therapies exist for LPP, high... Full story

Yahoo Finance • 2 months ago

New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis

The results of the Phase 3 VALOR trial were published in the New England Journal of Medicine, underscoring the practice-changing potential of brepocitinib 30 mg once-daily in dermatomyositis Brepocitinib 30 mg was superior to placebo on th... Full story

Yahoo Finance • 2 months ago

Bernstein Initiates Coverage of Roivant Sciences Ltd. (ROIV) with an Outperform Rating

Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the 12 Best UK Stocks to Buy According to Hedge Funds. On March 19, 2026, Bernstein initiated coverage of Roivant Sciences Ltd. (NASDAQ:ROIV) with an Outperform rating and a $35 price target,... Full story

Yahoo Finance • 2 months ago

A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you?

On February 17, 2026, Logos Global Management LP disclosed in a Securities and Exchange Commission filing that it bought 1,100,000 shares of Immunovant(NASDAQ:IMVT), an estimated $24.53 million trade based on quarterly average pricing. Lo... Full story